Although quite a few studies have shown that SIPL1 is amplified and overexpressed in many types of human malignancies, such as breast cancer, gastric cancer, and melanoma (6–8), some studies have demonstrated the tumor-suppressive role of SIPL1 in esophageal cancer progression (9). Here, SHARPIN is linked to breast cancer.